SSA
HRMY icon

Schonfeld Strategic Advisors’s Harmony Biosciences HRMY Stock Holding History

Schonfeld Strategic Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-68,116
Closed -$1.91M – 2779
2026
Q1 		$1.91M Buy
+68,116
New +$2.23M 0.01% 846
2024
Q3 		– Sell
-9,346
Closed -$282K – 2198
2024
Q2 		$282K Buy
+9,346
New +$281K ﹤0.01% 1714
2023
Q2 		– Sell
-28,932
Closed -$945K – 2294
2023
Q1 		$945K Buy
28,932
+24,048
+492% +$1.1M 0.01% 979
2022
Q4 		$269K Sell
4,884
-9,416
-66% -$518K ﹤0.01% 1847
2022
Q3 		$633K Buy
+14,300
New +$698K 0.01% 1584

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Schonfeld Strategic Advisors's HRMY Position: Q2 2026 in Review

Schonfeld Strategic Advisors sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 68,116 shares — an estimated $1.91M sold.

Schonfeld Strategic Advisors first reported a position in HRMY in Q3 2022 and held it in 5 quarters. The position peaked at $1.91M in Q1 2026. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Schonfeld Strategic Advisors reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 68,116 Harmony Biosciences shares in Q2 2026, an estimated $1.91M.
  • Schonfeld Strategic Advisors first reported a position in Harmony Biosciences in Q3 2022 and held it in 5 quarters.
  • Schonfeld Strategic Advisors's Harmony Biosciences position peaked at $1.91M in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.